Aug 2022;61(8):686-691
Ipharraguerre, Anika E
Youll typically need confirmed diabetes diagnosis with extensive lab documentation, documented failure of multiple first-line medications (step therapy), prescription from specified provider types, and regular reauthorization every 3-6 months
Keywords: acute interstitial nephritis, AIN, AKI, diffuse podocytopathy, GLP1 agonist, minimal change disease, podocytopathy, semaglutide INTRODUCTION Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin analogues that potentiate glucose-dependent insulin excretion, delay gastric emptying, suppress glucagon secretion and reduce appetite [1]
Paying attention to symptoms like nausea, fatigue, or changes in appetite can help you adjust meal timing, food choices, or portion sizes to better support your body